REGN — REGENERON PHARMACEUTICALS, INC. — Income statement
From the XBRL facts of the company's SEC filings. USD, millions, except per-share figures. Latest filing read: 2026-10-30.
Annual · Quarterly | Latest filing · As first reported | Download all statements (Excel)
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | TTM Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Revenues | 8,497.1 | 16,071.7 | 12,172.9 | 13,117.2 | 14,202.0 | 14,342.9 | 16,896.2‡ |
| Total revenues | 8,497.1 | 16,071.7 | 12,172.9 | 13,117.2 | 14,202.0 | 14,342.9 | 16,896.2‡ |
| Cost of revenues | 491.9 | - | - | - | - | - | - |
| Gross profit | 8,005.2‡ | - | - | - | - | - | - |
| Selling, general and administrative | 1,346.0 | 1,824.9 | 2,115.9 | 2,631.3 | 2,954.4 | 2,700.0 | 2,762.6‡ |
| R&D expenses | 2,647.0 | 2,860.1 | 3,592.5 | 4,439.0 | 5,132.0 | 5,850.2 | 6,595.9‡ |
| Other operating expenses, total | 435.6‡ | 2,439.9‡ | 1,725.6‡ | 1,999.8‡ | 2,124.9‡ | 2,214.8‡ | 2,673.2‡ |
| Operating income (GAAP, as reported) | 3,576.6 | 8,946.8 | 4,738.9 | 4,047.1 | 3,990.7 | 3,577.9 | 4,864.5‡ |
| Operating income excl. unusual items (S&P method) | 3,576.6‡ | 8,946.8‡ | 4,738.9‡ | 4,047.1‡ | 3,990.7‡ | 3,577.9‡ | - |
| Interest expense | 56.9 | 57.3 | 59.4 | 73.0 | 55.2 | 43.8 | 46.7‡ |
| Net interest expenses | (56.9)‡ | (57.3)‡ | (59.4)‡ | (73.0)‡ | (55.2)‡ | (43.8)‡ | (46.7)‡ |
| Other non-operating income (expenses) | 290.7 | 436.3 | 179.3 | 225.2 | 844.4 | 1,696.6 | 869.0‡ |
| Total unusual items | 0.0‡ | 0.0‡ | (195.0)‡ | - | - | - | - |
| EBT excl. unusual items | 3,810.4‡ | 9,325.8‡ | 5,053.8‡ | 4,199.3‡ | 4,779.9‡ | 5,230.7‡ | 5,686.8‡ |
| EBT incl. unusual items | 3,810.4 | 9,325.8 | 4,858.8 | 4,199.3 | 4,779.9 | 5,230.7 | 5,686.8‡ |
| Income tax expense | 297.2 | 1,250.5 | 520.4 | 245.7 | 367.3 | 725.8 | 869.4‡ |
| Earnings from continuing operations | 3,513.2‡ | 8,075.3‡ | 4,338.4‡ | 3,953.6‡ | 4,412.6‡ | 4,504.9‡ | 4,817.4‡ |
| Net income | 3,513.2 | 8,075.3 | 4,338.4 | 3,953.6 | 4,412.6 | 4,504.9 | 4,817.4‡ |
| NI to common incl. extra items | 3,513.2‡ | 8,075.3‡ | 4,338.4‡ | 3,953.6‡ | 4,412.6‡ | 4,504.9‡ | 4,817.4‡ |
| NI to common excl. extra items | 3,513.2‡ | 8,075.3‡ | 4,338.4‡ | 3,953.6‡ | 4,412.6‡ | 4,504.9‡ | 4,817.4‡ |
| Revenue per share | 78.97‡ | 152.05‡ | 113.66‡ | 122.94‡ | 131.62‡ | 137.12‡ | 164.24‡ |
| Basic EPS | 32.65 | 76.40 | 40.51 | 37.05 | 40.90 | 43.07 | 46.83‡ |
| Basic weighted average shares | 107.6 | 105.7 | 107.1 | 106.7 | 107.9 | 104.6 | 102.9‡ |
| Diluted EPS | 30.52 | 71.97 | 38.22 | 34.77 | 38.34 | 41.48 | 45.17‡ |
| Diluted weighted average shares | 115.1 | 112.2 | 113.5 | 113.7 | 115.1 | 108.6 | 106.7‡ |
| Normalized net income (S&P method, 37.5 %) | 2,381.5‡ | 5,828.6‡ | 3,158.6‡ | 2,624.6‡ | 2,987.4‡ | 3,269.2‡ | 3,554.3‡ |
| Normalized basic EPS (S&P method) | 22.13‡ | 55.14‡ | 29.49‡ | 24.60‡ | 27.69‡ | 31.25‡ | 34.55‡ |
| Normalized diluted EPS (S&P method) | 20.69‡ | 51.95‡ | 27.83‡ | 23.08‡ | 25.96‡ | 30.10‡ | 33.33‡ |
| EBITDA | 3,812.5‡ | 9,233.0‡ | 5,080.3‡ | 4,468.1‡ | 4,473.6‡ | 4,121.6‡ | 5,377.4‡ |
| EBIT | 3,576.6‡ | 8,946.8‡ | 4,738.9‡ | 4,047.1‡ | 3,990.7‡ | 3,577.9‡ | 4,864.5‡ |
| Effective tax rate | 7.8%‡ | 13.4%‡ | 10.7%‡ | 5.9%‡ | 7.7%‡ | 13.9%‡ | 15.3%‡ |
‡ derived by arithmetic from reported figures (a fourth quarter is the year less nine months). † read from a substitute line. § reported in a note, not on the face of the statement. “-” not reported. NM not meaningful. Normalized rows follow the S&P method: pre-tax income excluding unusual items, a flat 37.5 % tax rate, less minority interest.
By product or service
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | TTM Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| Collaboration Revenue | 1,186.1 | 3,673.3 | 4,914.1 | 5,503.1 | 6,057.8 | 7,331.2 | - |
| LIBTAYO Net Product Sales | - | 306.3 | 447.5 | 863.1 | 1,216.8 | 1,452.2 | - |
| Other Products | - | - | - | 0.0 | 0.0 | 10.1 | - |
| Product | 5,567.6 | 12,117.2 | 6,893.7 | 7,078.0 | 7,629.2 | 6,309.1 | - |
| Product And Service Other | 557.0 | 281.2 | 365.1 | 536.1 | 515.0 | 702.6 | - |
| Sanofi Collaboration Revenue | - | - | 2,855.7 | - | - | - | - |
By geography
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | TTM Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| US | - | 12,117.2 | 6,893.7 | - | - | - | - |
Segment figures as the company tagged them in its filings, one breakdown per table; members need not sum to the total.